Search clinical trials for: DAS181-F02 formulation

Total 2373 results

InQpharm Group

Completed

Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects

Hyperglycemia | Prediabetes

Germany
Shandong TheraWisdom Biopharma Co., Ltd.

Recruiting

Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

Advanced Malignancies

China
Calypso Biotech BV

Completed

Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Celiac Disease | Eosinophilic Esophagitis

Netherlands, Belgium, Finland, Germany, Norway
Minoryx Therapeutics, S.L.

Active, not recruiting

A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. (Advance)

Adrenoleukodystrophy

Spain, United States, Hungary, France, Germany, Italy, Netherlands, United Kingdom
Targovax Oy
Agenus Inc.

Withdrawn

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

Melanoma
Atriva Therapeutics GmbH

Terminated

Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19 (RESPIRE)

COVID-19

Germany, India, Netherlands, Poland, Romania, South Africa, Spain
Scilex Pharmaceuticals, Inc.
Worldwide Clinical Trials; Semnur Pharmaceuticals, Inc.

Completed

Corticosteroid Lumbar Epidural Analgesia for Radiculopathy

Lumbosacral Radicular Pain

United States
Orion Biotechnology Polska Sp. z o.o.
Scope International AG

Completed

OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults

HIV Prevention

Poland
University of Florida
Taiho Oncology, Inc.

Terminated

TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)

Pancreatic Cancer

United States
Array Biopharma, now a wholly owned subsidiary...

Completed

A Safety Study of ARRY-502 in Healthy Subjects

Healthy

United States
Prof. Dr. Dieter Willbold
Medical University of Vienna; Helmholtz-Gemeinschaft Deutscher Forschungszentren... and other collaborators

Completed

SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate

Alzheimer Disease | Alzheimer Dementia

Germany
GenSpera, Inc.
Saint John's Cancer Institute

Withdrawn

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

Glioblastoma

United States
Neothetics, Inc

Completed

Dose Ranging and Dose Frequency of LIPO-102

Subcutaneous Adipose Tissue Reduction

United States
Xenon Pharmaceuticals Inc.

Completed

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN) (XEN402)

Postherpetic Neuralgia

United States
Tranzyme, Inc.

Completed

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

Diabetes Mellitus | Gastroparesis

United States, Denmark, Norway, Sweden, United Kingdom, Poland
Abbott

Completed

A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects

Healthy Volunteers

United States
Butantan Institute
Fundação de Amparo à Pesquisa do Estado de São Paulo; Banco Nacional de Desenvolvimento... and other collaborators

Unknown

Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

Dengue

Brazil
Chong Kun Dang Pharmaceutical

Completed

A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects

GERD

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (GRC00097)

Influenza

United States
Taiho Oncology, Inc.

Completed

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Advanced Solid Tumors (Excluding Breast Cancer)

United States
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
GlaxoSmithKline

Terminated

Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery

Lung Cancer, Non-Small Cell

United States, France, Germany, Russian Federation, Poland, Italy
GlaxoSmithKline

Completed

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Melanoma

Germany, Czechia, France, Italy, Russian Federation, Poland
Xinhua Hospital, Shanghai Jiao Tong University...

Not yet recruiting

Radiotherapy Combined With Realgar-Indigo Naturalis Formula (RIF) in the Treatment of Rhabdomyosarcoma(RMS) in Children

Rhabdomyosarcoma, Child
Groupe Oncologie Radiotherapie Tete et Cou
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (TPEx)

Squamous Cell Head and Neck Carcinoma | Recurrent or Metastatic Disease

France, Belgium
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine

Influenza | Orthomyxoviridae Infections

United Kingdom
Lecia V. Sequist
Bristol-Myers Squibb; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical... and other collaborators

Terminated

Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

Non-small Cell Lung Cancer

United States
Maastricht Radiation Oncology
Merck Sharp & Dohme LLC; Academisch Ziekenhuis Maastricht

Completed

Phase I Cetuximab and Concurrent Radio-chemotherapy

Non-small Cell Lung Cancer

Netherlands
Sun Yat-sen University
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy (ENCORE)

Nasopharyngeal Carcinoma

China
Fudan University

Completed

Study of Cetuximab to Treat Gastric Cancer (STAGE)

Gastric Cancer

China
Ipsen

Completed

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours (CLARINET)

Endocrine Tumors

United States, United Kingdom, Netherlands, Belgium, Sweden, Spain, France, Denmark, India, Germany, Austria, Czechia, Italy, Poland, Slovakia
Ipsen

Completed

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Acromegaly

Australia
Ruijin Hospital
Henan Cancer Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang... and other collaborators

Unknown

Cetuximab Monotherapy Maintenance Treatment in mCRC

Colorectal Cancer
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer

Gastric Cancer

Germany
Spanish Cooperative Group for the Treatment of...
Merck Sharp & Dohme LLC

Terminated

Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.

Metastatic Colorectal Cancer

Spain
Sun Yat-sen University

Recruiting

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Pancreatic Neoplasms

China
Fab'entech

Recruiting

Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome

COVID-19

Greece
National University Hospital, Singapore

Recruiting

A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

Singapore
Inversago Pharma Inc.

Active, not recruiting

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Obesity | Metabolic Syndrome

Canada
LaNova Medicines Zhejiang Co., Ltd.

Active, not recruiting

Study of LM-302 in Patients With Advance Solid Tumors

Advanced Solid Tumor

China
Inversago Pharma Inc.

Completed

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

Metabolic Syndrome

Canada
Seoul National University Hospital
Threshold Pharmaceuticals

Completed

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Celularity Incorporated

Withdrawn

Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Diabetic Foot | Peripheral Arterial Disease

United States
InQpharm Group

Completed

Efficacy and Safety of IQP-AK-102 in Reducing Appetite

Appetite Regulation | Energy Intake | Appetite Suppression

Germany
Kyowa Kirin Co., Ltd.

Completed

The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study

Type 2 Diabetes | Chronic Kidney Disease

Japan
GenSpera, Inc.

Completed

Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

Clear Cell Renal Cell Carcinoma

United States
GenSpera, Inc.

Completed

G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer

Prostatic Neoplasms

United States
Xigen SA

Completed

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

Pain | Inflammation | Cataract

United States
Taiho Oncology, Inc.

Completed

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Advanced Solid Tumors (Excluding Breast Cancer)

United States
Neothetics, Inc

Completed

Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)

Thyroid-Related Eye Disease

Australia, New Zealand

Search clinical trials for: DAS181-F02 formulation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations